Access cutting-edge heart failure treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access heart failure specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related heart failure treatment provided free
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which remain poorly defined. In large clinical trials, semaglutide improved the outcomes in obese patients, patie
Sponsor: University Medical Centre Ljubljana
Check if you qualify for this heart failure clinical trial in Palo Alto, CA
If you're searching for heart failure treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.